Bristol-Myers Squibb (NYSE:BMY) Rating Lowered to Hold at Societe Generale

Share on StockTwits

Societe Generale lowered shares of Bristol-Myers Squibb (NYSE:BMY) from a buy rating to a hold rating in a research note published on Monday, 24/7 WallStreet reports. Societe Generale currently has $50.00 price target on the biopharmaceutical company’s stock.

BMY has been the subject of several other research reports. Mizuho started coverage on Bristol-Myers Squibb in a report on Monday, November 25th. They issued a buy rating for the company. Barclays started coverage on Bristol-Myers Squibb in a report on Thursday, February 27th. They issued an equal weight rating and a $69.00 price objective for the company. Citigroup raised Bristol-Myers Squibb from a neutral rating to a buy rating and set a $73.00 price objective for the company in a report on Monday, January 6th. ValuEngine raised Bristol-Myers Squibb from a strong sell rating to a sell rating in a report on Monday, March 9th. Finally, Gabelli started coverage on Bristol-Myers Squibb in a report on Wednesday, November 27th. They issued a buy rating for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $62.08.

Shares of BMY opened at $52.25 on Monday. The business has a 50-day moving average of $59.79 and a 200 day moving average of $58.38. Bristol-Myers Squibb has a fifty-two week low of $42.48 and a fifty-two week high of $68.34. The firm has a market cap of $111.16 billion, a P/E ratio of 23.86, a price-to-earnings-growth ratio of 0.96 and a beta of 0.78. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.37 and a current ratio of 1.60.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.34. Bristol-Myers Squibb had a return on equity of 31.85% and a net margin of 13.15%. The company had revenue of $7.95 billion during the quarter, compared to analyst estimates of $6.20 billion. During the same quarter last year, the firm posted $0.94 EPS. The firm’s revenue for the quarter was up 33.0% on a year-over-year basis. As a group, research analysts predict that Bristol-Myers Squibb will post 6.15 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Friday, April 3rd will be issued a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a yield of 3.44%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol-Myers Squibb’s payout ratio is presently 38.38%.

In other Bristol-Myers Squibb news, EVP John E. Elicker sold 15,805 shares of Bristol-Myers Squibb stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $61.01, for a total transaction of $964,263.05. Following the completion of the transaction, the executive vice president now owns 58,666 shares of the company’s stock, valued at approximately $3,579,212.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.13% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the business. Wealth Quarterback LLC bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $11,012,211,000. Charles Schwab Investment Management Inc. boosted its position in shares of Bristol-Myers Squibb by 42.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 19,662,473 shares of the biopharmaceutical company’s stock valued at $1,262,135,000 after acquiring an additional 5,861,939 shares during the last quarter. Capital World Investors boosted its position in shares of Bristol-Myers Squibb by 2.4% during the 4th quarter. Capital World Investors now owns 12,705,535 shares of the biopharmaceutical company’s stock valued at $815,568,000 after acquiring an additional 303,014 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Bristol-Myers Squibb by 42.5% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,527,341 shares of the biopharmaceutical company’s stock valued at $671,013,000 after acquiring an additional 3,140,646 shares during the last quarter. Finally, TIG Advisors LLC boosted its position in shares of Bristol-Myers Squibb by 9,590.9% during the 4th quarter. TIG Advisors LLC now owns 9,348,540 shares of the biopharmaceutical company’s stock valued at $28,139,000 after acquiring an additional 9,447,040 shares during the last quarter. 77.88% of the stock is owned by institutional investors and hedge funds.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: What is the G-20?

Analyst Recommendations for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Q2 2020 EPS Estimates for Agnico Eagle Mines Ltd Cut by Cormark
Q2 2020 EPS Estimates for Agnico Eagle Mines Ltd Cut by Cormark
Q2 2020 Earnings Estimate for W. R. Grace & Co Issued By Jefferies Financial Group
Q2 2020 Earnings Estimate for W. R. Grace & Co Issued By Jefferies Financial Group
Q2 2020 Earnings Forecast for Element Fleet Management Corp  Issued By Cormark
Q2 2020 Earnings Forecast for Element Fleet Management Corp Issued By Cormark
Trevali Mining Corp Forecasted to Post Q2 2020 Earnings of  Per Share
Trevali Mining Corp Forecasted to Post Q2 2020 Earnings of Per Share
Vornado Realty Trust to Post Q2 2020 Earnings of $0.77 Per Share, Piper Sandler Forecasts
Vornado Realty Trust to Post Q2 2020 Earnings of $0.77 Per Share, Piper Sandler Forecasts
Green Plains Partners  Downgraded by Zacks Investment Research
Green Plains Partners Downgraded by Zacks Investment Research


 
© 2006-2020 Zolmax.